How a rare pediatric neoplasia can give important insights into biological concepts: A perspective on juvenile myelomonocytic leukemia

Haematologica

Volumn 92, Issue 11, 2007, Pages 1441-1446

  Flotho, Christian ^a   Kratz, Christian P ^a   Niemeyer, Charlotte M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYTARABINE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANOSINE DIPHOSPHATE; HEMOGLOBIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAS PROTEIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER SURVIVAL; CHILDHOOD CANCER; DIFFERENTIAL DIAGNOSIS; EDITORIAL; GENE DELETION; HETEROZYGOSITY LOSS; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA CELL; LOW DRUG DOSE; MONOSOMY 7; MYELOPROLIFERATIVE DISORDER; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; POINT MUTATION; SOMATIC MUTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT INDICATION;

CHILD; DIAGNOSIS, DIFFERENTIAL; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; RAS PROTEINS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 36348932201     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11280     Document Type: Editorial

References (60)

1. Niemeyer CM, Locatelli F. Chronic myeloproliferative disorders. In: Pui CH, editor. Childhood Leukemia. New York: Cambridge University Press; 2006.571-98.
2. Niemeyer CM, Arico M, Basso G, Biondi A, Cantù-Rajnoldi A, Creutzig U, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood 1997;89:3534-43.
3. Niemeyer CM, Fenu S, Hasle H, Mann G, Stary J, van Wering E. Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 1998;91:365-7.
4. Weatherall DJ, Edwards JA, Donohoe WT. Haemoglobin and red cell enzyme changes in juvenile myeloid leukaemia. Br Med J 1968;1:679-81.
5. Bergsträßer E, Hasle H, Rogge T, Fischer A, Zimmermann M, Nöllke P, et al. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: A retrospective analysis and definition of response criteria. Pediatr Blood Cancer 2007;49:629-33.
6. Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia QMML): results of the EWOG-MDS/EBMT trial. Blood 2005; 105:410-9.
7. Bernard J, Seligmann M, Acar J. La leucémie myeloide chronique de l'enfant. Étude de vingt observations. Arch Fr Pediatr 1962;19:881-4.
8. Hardisty RM, Speed DE, Morwenna T. Granulocytic leukemia in childhood. Br J Haematol 1964;10:551-66.
9. Vardiman JW. Myelodysplastic / myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. 47-59.
10. Sieff CA, Chessells JM, Harvey BAM, Pickthall VJ, Lawler SD. Monosmy 7 in childhood: a myeloproliferative disorder. Br J Haematol 1981;49:235-49.
11. Hasle H, Arico M, Basso G, Biondi A, Cantù-Rajnoldi A, Creutzig U, et al. Myelodysplastic syndrome and acute myeloid leukemia associated with complete or partial monosomy 7. Leukemia 1999;13:376-85.
12. Altman AJ, Palmer CG, Baehner RL. Juvenile "chronic granulocytic" leukemia: a panmyelopathy with prominent monocytic involvement and circulating monocyte colony-forming cells. Blood 1974;43:341-50.
13. Emanuel PD, Bates LJ, Zhu SW, Castleberry RP, Gualtieri RJ, Zuckerman KS. The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. Exp Hematol 1991;19:1017-24.
14. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991;77:925-9.
15. Lanfrancone L, Pelicci G, Brizzi MF, Arouica MG, Casciari C, Giuli S, et al. Overexpression of She proteins potentiates the proliferative response to the granulocyte-macrophage colony-stimulating factor and recruitment of Grb2/SoS and Grb2/p140 complexes to the β receptor subunit. Oncogene 1995;10:907-17.
16. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
17. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature 1990;348:125-32.
18. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993;366:643-54.
19. Repasky GA, Chenette EJ, Der CJ. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol 2004;14:639-47.
20. Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 2002;1602:23-45.
21. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
22. Kalra R, Paderanga DC, Olson K, Shannon KM. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 1994;84:3435-9.
23. Flotho C, Valcamonica S, Mach-Pascual S, Schmahl G, Corral L, Ritterbach J, et al. Ras mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999;13:32-7.
24. Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006;38:331-6.
25. Matsuda K, Shimada A, Yoshida N, Ogawa A, Watanabe A, Yajima S, et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 2007;109:5477-80.
26. Matsuda K, Nakazawa Y, Sakashita K, Shiohara M, Yamauchi K, Koike K. Acquirement of loss of the wild-type NRAS locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation. Haematologica 2007;1576-8.
27. Xu GF, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990;62:599-608.
28. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, et al. Loss or NF1 results in activation or the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996;12:144-8.
29. Side L, Taylor B, Cayouette M, Conner E, Thompson P, Luce M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997;336:1713-20.
30. Stephens K, Weaver M, Leppig KA, Maruyama K, Emanuel PD, Le Beau MM, et al. Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood 2006; 108:1684-9.
31. Flotho C, Steinemann D, Mullighan CG, Neale G, Mayer K, Kratz CP, et al. Genome-wide single nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene 2007;26:5816-21.
32. Tartaglia M, Memeyer CM, Song X, Buechner J, Hählen K, Hasle H, et al. Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003;34:148-50.
33. Bader-Meunier B, Tchernia G, Mielot F, Fontaine JL, Thomas C, Lyonnet S, et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 1997;130:885-9.
34. Noonan JA. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 1968;116:373-80.
35. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465-8.
36. Niihori T, Aoki Y, Ohashi H, Kurosawa K, Kondoh T, Ishikiriyama S, et al. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. J Hum Genet 2005;50:192-202.
37. Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003;28:284-93.
38. Schubbert S, Lieuw K, Rowe SL, Lee CM, Li X, Loh ML, et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 2005;106:311-7.
39. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, et al. Germline gain-of-function mutations in SOSl cause Noonan syndrome. Nat Genet 2007;39:70-4.
40. Kratz CP, Niemeyer CM, Thomas C, Bauhuber S, Matejas V, Bergsträßer E, et al. Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia. Leukemia 2007;21:1108-9.
41. de Vries ACH, Stam RW, Kratz CP, Zenker M, Niemeyer CM, van den Heuvel-Eibrink MM. Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia. Haematologica 2007;92:1574-5.
42. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007; 1007-12.
43. Busque L, Gilliland DG, Prchal JT, Sieff CA, Weinstein HJ, Sokol JM, et al. Clonality in juvenile chronic myelogenous leukemia. Blood 1995;85:21-30.
44. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumor predisposition in mice heterozygous for a targeted mutation in NF1. Nat Genet 1994;7:353-61.
45. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 2004;101:597-602.
46. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, et al. Mouse model of Noonan syndrome reveals cell type-and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 2004;10:849-57.
47. Downing JR, Shannon KM. Acute leukemia: a pediatric perspective. Cancer Cell 2002;2:437-45.
48. de Vries ACH, Stam RW, Schneider P, Niemeyer CM, van Wering E, Haas OA, et al. Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia. Haematologica 2007;1557-60.
49. Lutz P, Zix-Kieffer I, Souillet G, Bertrand Y, Dhooge Y, Rubie H, et al. Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC childrens leukemia cooperative group (CLCG). Bone Marrow Transplant 1996;18:1111-6.
50. Woods WG, Barnard DR, Alonzo TA, Buckley JD, Kobrinsky N, Arthur DC, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol 2002;20:434-40.
51. Yoshimi A, Mohamed M, Bierings M, Urban C, Korthof E, Zecca M, et al. Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia 2007;21:556-60.
52. Castleberry RP, Emanuel PD, Zuckerman KS, Cohn S, Strauss L, Byrd RL, et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 1994; 331:1680-4.
53. Pui CH, Arico M. Isotretinoin for juvenile chronic myelogenous leukemia. N Engl J Med 1995;332:1520-1.
54. Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 2000;95:639-45.
55. Castleberry RP, Loh ML, Jayaprakash N, Peterson A, Casey V, Chang M, et al. Phase II window study of the farnesyltransferase inhibitor R115777 (Zarnestra®) in untreated juvenile myelomonocytic leukemia (JMML): a Children's Oncology Group study. Blood 2005;106:727a[abstract].
56. Bernard F, Thomas C, Emile JF, Hercus T, Cassinat B, Chomienne C, et al. Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood 2002;99:2615-6.
57. Aiyagari AL, Taylor BR, Aurora V, Young SG, Shannon KM. Hematologic effects of inactivating the Ras processing enzyme Reel. Blood 2003;101:2250-2.
58. Shimada H, Shima H, Shimasaki N, Yoshihara H, Mori T, Takahashi T. Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation. Ann Oncol 2005;16:1400.
59. Flotho C, Kratz CP, Niemeyer CM. Targeting RAS signaling pathways in juvenile myelomonocytic leukemia. Curr Drug Targets 2007;8:715-25.
60. Archambeault S, Yoshimi A, Kratz C, Reising M, Fischer A, Noellke P, et al. Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia-moving beyond clinical assessment. Blood 2006;108:758a[abstract].